Oak Ridge National Laboratory scientists exploring bioenergy plant genetics have made a surprising discovery: a protein domain that could lead to new COVID-19 treatments.
Researchers found the same plasminogen-apple-nematode, or PAN, domain studied by ORNL in plants like poplar and willow is also present in the human NRP1 receptor protein. NRP1 is less studied than the ACE-2 receptor targeted by current COVID-19 treatments, but this research shows its promise as a future therapeutic target.
By mutating amino acids called cysteine residues in the PAN domain of NRP1, researchers disrupted the ability of the SARS-CoV-2 virus to use its spike protein to invade cells, as described in iScience . ORNL scientists have also linked PAN to the growth of cancerous tumors .
“This project provides more evidence that PAN is involved in host cell invasion,” said ORNL’s Wellington Muchero. “By pinpointing these amino acids, researchers could reduce viral interaction with host cells.”
Collaborators include Debjani Pal, Kuntal De and Timothy Yates of ORNL; and Jaydeep Kolape of the University of Tennessee.
UT-Battelle manages ORNL for the Department of Energy’s Office of Science, the single largest supporter of basic research in the physical sciences in the United States. The Office of Science is working to address some of the most pressing challenges of our time. For more information, please visit energy.gov/science . — Stephanie Seay
iScience
Mutating novel interaction sites in NRP1 reduces SARS-CoV-2 spike protein internalization
21-Apr-2023